|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
US4615885A
(en)
|
1983-11-01 |
1986-10-07 |
Terumo Kabushiki Kaisha |
Pharmaceutical composition containing urokinase
|
|
JPS62126123A
(ja)
*
|
1985-11-28 |
1987-06-08 |
Shigeki Suzuki |
バルプロ酸の経皮吸収方法
|
|
JPH06510290A
(ja)
*
|
1991-08-27 |
1994-11-17 |
シグナス，インコーポレイテッド |
プラゾシンを投与するための経皮処方物
|
|
AU701737B2
(en)
|
1995-04-07 |
1999-02-04 |
Novartis Ag |
Iontophoretic transdermal system for the administration of at least two substances
|
|
US5736154A
(en)
|
1996-03-11 |
1998-04-07 |
Fuisz Technologies Ltd. |
Transdermal delivery system
|
|
FR2749514B1
(fr)
|
1996-06-11 |
1998-08-07 |
Hoechst Marion Roussel |
Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
|
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
WO1998031369A1
(fr)
|
1997-01-16 |
1998-07-23 |
Sekisui Chemical Co., Ltd. |
Preparations a usage externe a absorption percutanee
|
|
EP1093348A4
(en)
|
1998-06-29 |
2003-07-16 |
Pharmaceuticals Applic Asociat |
TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
|
|
AU780454B2
(en)
|
1999-06-03 |
2005-03-24 |
Jessie L.S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
IL138686A0
(en)
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
|
AU7788701A
(en)
*
|
2000-07-14 |
2002-01-30 |
Transform Pharmaceuticals Inc |
System and method for optimizing tissue barrier transfer of compounds
|
|
US6682757B1
(en)
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
BR0215102A
(pt)
*
|
2001-12-13 |
2004-11-03 |
Vital Health Sciences Pty Ltd |
Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
|
|
US6841565B1
(en)
*
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
|
US7652061B2
(en)
|
2003-05-20 |
2010-01-26 |
Novartis A.G. |
N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors
|
|
JP2009513523A
(ja)
|
2003-07-08 |
2009-04-02 |
ノバルティス アクチエンゲゼルシャフト |
ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
US8012944B2
(en)
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
|
EP1689702B1
(en)
|
2003-11-26 |
2013-01-30 |
Novartis AG |
Organic compounds
|
|
WO2005065668A2
(en)
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
WO2005105009A1
(en)
|
2004-04-26 |
2005-11-10 |
Cassel Douglas R |
Wound treatment patch for alleviating pain
|
|
KR100602434B1
(ko)
|
2004-09-10 |
2006-07-19 |
최상식 |
복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
|
|
CA2619568A1
(en)
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services |
Topical formulations of histone deacetylase inhibitors and methods of using the same
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070197957A1
(en)
|
2005-10-03 |
2007-08-23 |
Hunter William L |
Implantable sensors, implantable pumps and anti-scarring drug combinations
|
|
BRPI0520686A2
(pt)
|
2005-11-16 |
2009-05-19 |
Univ Mexico Nacional Autonoma |
uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
|
|
EP3000480A1
(en)
|
2005-12-01 |
2016-03-30 |
ProNAi Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
|
WO2007067695A2
(en)
|
2005-12-07 |
2007-06-14 |
University Of Utah Research Foundation |
Dna methylation as a target for diagnosis and treatment of chronic lymphocytic leukemia (cll)
|
|
JP5468782B2
(ja)
|
2006-03-02 |
2014-04-09 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
癌治療と幹細胞調節のための方法
|
|
US8585753B2
(en)
|
2006-03-04 |
2013-11-19 |
John James Scanlon |
Fibrillated biodegradable prosthesis
|
|
WO2007109178A2
(en)
|
2006-03-16 |
2007-09-27 |
Pharmacyclics, Inc. |
Indole derivatives as inhibitors of histone deacetylase
|
|
ES2444890T3
(es)
|
2006-03-31 |
2014-02-27 |
Erasmus University Medical Center Rotterdam |
Nueva composición para el control del crecimiento tumoral
|
|
ATE516020T1
(de)
*
|
2006-05-05 |
2011-07-15 |
Coloplast As |
Haftklebstoffzusammensetzung, enthaltend vernetztes polyalkylenoxid und wasserabsorbierende hydrophile mittel
|
|
WO2008082646A2
(en)
|
2006-12-28 |
2008-07-10 |
The Johns Hopkins University |
Histone deacetylase inhibitors, combination therapies and methods of use
|
|
EP2491923A3
(en)
|
2007-02-15 |
2012-12-26 |
Novartis AG |
Combinations of therapeutic agents for treating cancer
|
|
WO2008116163A1
(en)
|
2007-03-22 |
2008-09-25 |
Oregon Health & Science University |
Therapeutic drug combinations for treatment of b-cell malignancies
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
US8216571B2
(en)
|
2007-10-22 |
2012-07-10 |
Schering Corporation |
Fully human anti-VEGF antibodies and methods of using
|
|
WO2009067543A2
(en)
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
HUE055911T2
(hu)
|
2008-05-15 |
2021-12-28 |
Celgene Corp |
Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
|
|
WO2009155477A1
(en)
|
2008-06-19 |
2009-12-23 |
The Trustees Of The University Of Pennsylvania |
Inducible regulatory t-cell generation for hematopoietic transplants
|
|
WO2010020787A1
(en)
|
2008-08-22 |
2010-02-25 |
Oncomethylome Sciences Sa |
Diagnosis and treatment of tumours
|
|
DK2433124T3
(en)
*
|
2009-05-19 |
2017-06-19 |
Vivia Biotech Sl |
PROCEDURES FOR PROVIDING PERSONALIZED MEDICAL EX VIVO TESTS FOR HEMATOLOGICAL NEOPLASMS
|
|
US8491927B2
(en)
*
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
JP5548470B2
(ja)
*
|
2010-02-16 |
2014-07-16 |
日本碍子株式会社 |
ハニカム触媒体
|
|
US20110245154A1
(en)
*
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
|
EP2382993A1
(en)
*
|
2010-04-19 |
2011-11-02 |
KTB Tumorforschungsgesellschaft mbH |
Combination of drugs with protein-binding prodrugs
|
|
WO2012044936A1
(en)
*
|
2010-09-30 |
2012-04-05 |
Portola Pharmaceuticals, Inc. |
Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
|
|
DK2786753T3
(en)
*
|
2010-11-12 |
2019-04-15 |
Pharma Mar Sa |
Combination therapy with an antitumor antibiotic
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
JP2014513079A
(ja)
*
|
2011-04-08 |
2014-05-29 |
アフラクシス・ホールディングス・インコーポレイテッド |
神経系疾患及び癌の治療のための８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
|
|
US10941399B2
(en)
*
|
2011-04-14 |
2021-03-09 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
|
|
US20140170148A1
(en)
*
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
JP2014519813A
(ja)
*
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
BR112013033534A2
(pt)
*
|
2011-06-28 |
2017-02-07 |
Pharmacyclics Inc |
métodos e composições para inibição de reabsorção de osso
|
|
TW201700103A
(zh)
*
|
2011-11-01 |
2017-01-01 |
西建公司 |
利用胞嘧啶核苷類似物之口服配方治療癌症的方法
|
|
US20130158043A1
(en)
*
|
2011-12-09 |
2013-06-20 |
Afraxis, Inc. |
Pak inhibitors for the treatment of cancer
|
|
EP2854811A1
(en)
*
|
2012-05-31 |
2015-04-08 |
Amgen Inc. |
Use of amg 900 for the treatment of cancer
|
|
WO2013184572A1
(en)
*
|
2012-06-04 |
2013-12-12 |
Pharmacyclics, Inc. |
Crystalline forms of a bruton's tyrosine kinase inhibitor
|
|
WO2014009319A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
WO2014009318A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
TR201904785T4
(tr)
*
|
2012-08-09 |
2019-05-21 |
Celgene Corp |
(S)-3-(4-((4-MORFOLINOMETİL)BENZİL)OKSİ)-1-OKSOİZOİNDOLİN-2-il)PİPERİDİN-2,6-DİON HİDROKLORİDİN BİR KATI FORMU.
|
|
CN114366746A
(zh)
*
|
2012-08-09 |
2022-04-19 |
细胞基因公司 |
使用氧代异吲哚化合物治疗癌症
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
WO2014028560A2
(en)
*
|
2012-08-14 |
2014-02-20 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US20140120083A1
(en)
*
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
AU2013360335B2
(en)
*
|
2012-12-13 |
2017-12-07 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|